Innovation is undoubtedly the key element in China’s healthcare investment scenario and early-stage venture capital funds continue to back home-grown new drug development with a total of 15 deals in the third quarter. The biggest deal was valued at up to $66m.
In the healthcare sector, China and the US are riding the same trend, noted Tim Hardin, vice president, SPD Silicon...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

